1 / 79

Oncology management of CNS tumours Neil Burnet

Oncology management of CNS tumours Neil Burnet. University of Cambridge Department of Oncology & Oncology Centre, Addenbrooke’s Hospital. ECRIC CNS study day 7 th April 2009. Introduction . Treatment modalities for cancer What data do oncologists want? Examples of uses of Registry data.

noam
Télécharger la présentation

Oncology management of CNS tumours Neil Burnet

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Oncology management of CNS tumoursNeil Burnet University of Cambridge Department of Oncology & Oncology Centre, Addenbrooke’s Hospital ECRIC CNS study day 7th April 2009

  2. Introduction • Treatment modalities for cancer • What data do oncologists want? • Examples of uses of Registry data

  3. Cancer treatment modalities

  4. Cancer treatment modalities • Modalities • (Surgery) • Radiotherapy • Chemotherapy • Consider efficacy • Consider costs

  5. Oncology management

  6. Radiotherapy • Radiotherapy is an anatomical treatment • Treats a specific area • Localising the tumour target is crucial • Imaging is key • Better localisation – better outcome • Localising normal structures allows avoidance

  7. CT – the technology advance Late 1970s 1980s 2003

  8. Glioblastoma imaging • T2 • T1 • T1 + Gd contrast MR (magnetic resonance) imaging

  9. Radiotherapy • Immobilise the patient • Relate today's patient position to tumour imaging

  10. Radiotherapy • High precision positioning • Relocatable stereotactic frame

  11. Radiotherapy

  12. Radiotherapy imaging CT MRI

  13. GBM planning • Using CT +MR together MRI CT

  14. Radiotherapy imaging • Post-op planning CT • Pre-op CT

  15. Target volume delineation

  16. Radiotherapy • Planning and delivery technology now very different • Old ‘square’ planning • Was conventional in 1960s – 1990s • Conformal (dose conforms to shape of target in 3D) • ‘Ultra-conformal’ (includes concave shape) • known as IMRT (intensity modulated radiotherapy) • 21st century technology

  17. Treatment volumes compared Conformal Ultra-conformal IMRT ‘Square’ plan

  18. Old ‘square’ planning

  19. Some shielding with ‘lead’ blocks

  20. Treatment volumes compared Conformal Ultra-conformal IMRT ‘Square’ plan

  21. Conformal RT plan

  22. IMRT plan (TomoTherapy) • Ca nasopharynx • 68 Gy to primary (34#) • 60 Gy to nodes (34#) • Cord dose < 45 Gy • No field junctions • No electrons

  23. IMRT plan • Skull base meningioma • Shaping of dose around optic nerves and chiasm • Tumour ~60 Gy • Optic chiasm 50 Gy

  24. Radiotherapy dose • Biological effect depends on • Total dose • Number of fractions (Dose per fraction) • Overall treatment time Complex relationship

  25. Radiotherapy dose • Single fraction • Very destructive • Known as radiosurgery • Must physically avoid normal tissue • Multiple fractions • Spare normal tissue • Enhances therapeutic radio • Allows treatment including normal tissue

  26. RT dose and fractions • For a given dose, and overall time, biological effect depends on number of # • Actually depends on dose/#

  27. Chemotherapy • Use in accordance with NICE Guidelines • At first presentation, with (surgery &) RT • Temozolomide • Also at relapse • PCV • Monitor • Blood count, nausea, liver function (+ other s/e) • Progression

  28. Chemotherapy • Most chemo for CNS tumours is oral • Temozolomide • Invented in UK • Revolutionised treatment of GBM

  29. RT + TMZ for GBM EORTC Randomised trial results P<0.001

  30. Cancer cure and cost

  31. Cancer cures by modality • References • SBU. The Swedish council on technology assessment in health care: Radiotherapy for Cancer. 1996 • Cancer Services Collaborative 2002

  32. The Cancer Reform Strategy Prof. Mike Richards 2007

  33. Effectiveness and cost % cures % of cancer Ratio care cost • Radiotherapy 40% 5% 8.0 • Chemotherapy 11% 18% 0.6 • Surgery 49% 22% 2.2

  34. What data do oncologists really want?

  35. What data do oncologists really want? • What data do oncologists really want or need? • Types of CNS tumour • Prognostic factors • Treatment intent • Treatment details • Dates

  36. Tumour types in oncology clinic • Note ~20% with benign tumours

  37. CNS tumour types - 1 • Glial tumours • Astrocytoma (inc Pilocytic & Juvenile Pilocytic) • Oligodendroglioma • Oligo-astrocytoma • Glioblastoma (GBM) • Ependymoma (+ subependymoma) • Meningioma • Pituitary adenoma + Craniopharyngioma

  38. CNS tumour types - 2 • Vestibular schwannoma (aka acoustic neuroma) • Medulloblastoma • Germinoma + teratoma • Lymphoma • Neurocytoma + Ganglioglioma • Pineoblastoma • Primitive neuro-ectodermal tumour (PNET) • (Chordoma + chondrosarcoma) • (Metastases)

  39. CNS tumour types - 3 • Many tumour types • Prognosis varies enormously • Survival from “days to weeks” to cure • Affected by tumour type • Grade (ie how malignant) • Essential to know detail • Detail must be collected

  40. Grade affects prognosis • High grade glioma • Grade III • Grade IV = GBM - Surgery + RT only - Radical treatment - Addenbrooke’s data

  41. Grade affects prognosis • Histology is not the only tumour feature which affects outcome

  42. Radiotherapy & Oncology 2007; 85:371-378 • Radiology adds to pathology grade • Need to include information from imaging

  43. What data do oncologists really want? • Prognostic factors • Age • Performance status • ? Size • Extent of surgical resection (hard to evaluate) • Treatment intent • Radical • Palliative

  44. What data do oncologists really want? • Treatment intent • Might be clear from treatment • GBM – RT 60 Gy (30#) = radical 30 Gy (6#) = palliative • Need to know if intent changes • eg due to progression

  45. Radiotherapy details • Area treated • Total dose • Number of fractions • Overall treatment time • Dates • Time (delay) to start RT • Overall time (duration) of RT

  46. Chemotherapy details • Drug(s) • Dose • Number of cycles given • Dates

More Related